Preliminary findings, although based on a small sample, suggest initial signals that CASA may improve well-being and overall quality of life for both patients and caregivers, while reducing symptoms of anxiety, depression, and emotional distress. The gene discussed is CSN1S1; the disease is depressive symptom measurement.